>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: DOV -6.8%

M&A news:
  • TWTR -13.1% (Bloomberg reports that potential suitors have lost interest, won't bid for the company)
Select EU financial related names showing weakness:
  • RBS -2.2%, BCS -0.9%, PUK -0.9%, LYG -0.8%
Other news:
  • OPTT -15.1% (launches underwritten public offering of 2.5 mln shares of its common stock)
  • BMY -6.4% (several presentations at ESMO conf)
  • TWLO -5.9% (files for $400 mln offering of common stock by it and various selling shareholders)
  • NVO -1.8% (receives Complete Response Letter from the FDA regarding the New Drug Application for faster-acting insulin aspart)
  • VIV -1.7% (appoints Eduardo Navarro as president and CEO of Telefonica Brazil)
Analyst comments:
  • MYGN -5.4% (downgraded to Sell from Neutral at Ladenburg Thalmann)
  • UTX -1.7% (downgraded to Neutral from Buy at Citigroup)
  • NFLX -1.4% (initiated with a Sell at Deutsche Bank)
  • HVT -0.8% (downgraded to Mkt Perform at Raymond James)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: NXTD +17.6%, MOBL +14.1%

M&A news:
  • EGAS +69.1% (agrees to be acquired by First Reserve for $13.10/share in cash)
  • AYA +2.7% (confirms discussions with William Hill PLC are ongoing),
  • SU +0.9% (mulling a potential sale of its of its Petro-Canada retail gasoline station unit, according to Reuters)
Select metals/mining stocks trading higher: DRD +2.9%, PAAS +2.5%, AG +2.4%, AUY +2.2%, MT +1.9%, ABX +1.3%,SLV +0.8%

Other news:
  • IPCI +15.5% (receives FDA tentative approval for generic Seroquel XR)
  • TSRO +15% (present successful Niraparib Phase 3 results of ENGOT-OV16/NOVA trial)
  • MYL +11.6% (agrees to settlement on Medicaid rebate classification for EpiPen Auto-Injector, lowers FY16 EPS guidance; also upgraded to Strong Buy from Market Perform at Raymond James)
  • MZOR +7.4% (Mazor Robotics receives first pre-launch orders for Mazor X System)
  • CLDX +6% (reports Phase 2 Study of Glembatumumab Vedotin met primary overall response endpoint)
  • EXEL +4.9% (Exelixis and Ipsen (IPSEY) report Phase 2 study of Cabozantinib met the primary endpoint of improving progression-free survival)
  • CASC +4% (presentation of tucatinib in combination therapy in patients with cutaneous HER2+ metastatic breast cancer)
  • LPCN +3.5% (cont strength after Friday's announcement of U.S. District Court in Delaware granted its motion to dismiss a lawsuit filed by Clarus Therapeutics)
  • MRK +3.3% (announced findings from the final overall survival analysis from the KEYNOTE-002 study)
  • CRM +2.9% (reports that co is no longer interesting in offer for TWTR)
  • TSLA +2.2% (Elon Musk in series of tweets teases October 17 product unveiling, says it and SolarCity (SCTY) won't need to raise debt or equity in Q4)
  • IONS +2.1% (Biogen (BIIB) and Ionis Pharmaceuticals (IONS) presented new data from the clinical program for nusinersen)
  • VRX +2% (in sympathy with MYL)
  • TEVA +1.9% (in sympathy with MYL)
  • PRGO +1.4% (in sympathy with MYL)
Analyst comments:
  • UA +2.5% (upgraded to Outperform from Market Perform at Wells Fargo )
  • ATHN +2% (upgraded to Buy from Hold at Evercore ISI)
  • DE +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
  • TSN +1.2% (upgraded to Buy from Outperform at CLSA)
  • STO +0.8% (added to European Focus List at Citigroup)

DJ Bid Could Value Osram at More Than EUR70/Share, Says LBBW -- Market Talk

DJ Bid Could Value Osram at More Than EUR70/Share, Says LBBW -- Market Talk
1152 GMT Osram shares have surged by about a third since their September low, which LBBW attributes to expectations of a possible takeover bid for the German lighting company. Siemens has voiced opposition against Osram's expansion in the field of chips for general lighting, therefore it would be consistent if Siemens sold its 17.5% stake in Osram, in LBBW's view. A bidder could offer more than EUR70 per Osram share, the bank says, pointing to multiples implied by Go Scale Capital's failed bid for Philips' lighting business. Osram declined to comment on a possible takeover bid. LBBW raises the target price for Osram to EUR57 from EUR41 and maintains a hold recommendation. Shares trade 0.7% lower at EUR57.30.

>>> US Early premarket gappers


Early premarket gappers

Gapping up: IPCI +47.1%, MYL +12.4%, TSRO +10.1%, IONS +7.2%, CLDX +6.3%, EXEL +6.2%, SDRL +5.4%, DRD +3.9%, AG +3.5%, AUY +3%, VRX +2.9%, MRK +2.9%, PAAS +2.5%, TSLA +2.4%, CRM +2.2%, SCTY +2.1%, AVP +2.1%, TEVA +2%, MT +1.7%, GG +1.7%, PBR +1.6%, UA +1.5%, ABX +1.4%, SLV +1.4%, PRGO +1.3%, GDX +1.3%, NEM +1.2%, RDS.A +1.1%

Gapping down: TWTR -8.3%, BMY -6.2%, VIV -2.1%, SYT -2%, NFLX -1.7%, DOV -1.6%, NVO -1.4%, UTX -1.4%, LYG -1.1%, BCS -1%, AZN -1%, DB -0.7%

FT : Computer revolution? Good investments still need the human touch

Computer revolution? Good investments still need the human touch
Smart beta approaches risk making dumb mistakes
Parts of the modern investment industry appear to view reading through company accounts as like hand-washing dishes or waiting in the rain to hail a taxi — a loathsome task that will eventually be eliminated by technology.

Leading this trend are so-called smart beta funds — a booming area of investment management that seeks out magic formulas to screen for stocks with characteristics proven to “beat the market”, and distils them into simple, low-cost index-like products.

The strategy, which has enjoyed tens of billions of dollars of inflows, has come under criticism of late for its vulnerability to suffocating itself. If too much money chases the same winning “factors”, such as cheapness or price momentum, then the advantage gained from doing so will be arbitraged away.

Less frequently discussed is the mechanistic approach these smart funds employ to screen for supposedly “fundamental” features of the companies in which they invest. Stock screens were in the past intended to be exclusionary rather than inclusionary tools, meaning they filter out investments that do not match certain criteria and allow for closer examination of those that do. By inverting this process — seeking to invest solely on the basis of what the screen says — certain smart beta funds appear at risk of making some dumb mistakes.

One popular type of smart beta approach is to screen for “quality income stocks”, or shares that offer a solid and dependable dividend. Billions of dollars have in recent years poured into exchange traded funds that invest on this basis, with investors relying on faith that the quantitative models will keep their cash safe. Société Générale, for example, publishes a screen seeking out “attractive and sustainable dividends” using a methodology very similar to some of these smart beta ETFs. Its model right now indicates that AstraZeneca, the UK-listed pharma company, is a strong pick.

SocGen’s quant screen that tells us AstraZeneca’s high dividend is solid is based on two neat formulas. The “quality” of a dividend payer’s earnings is calculated using what is known as a Piotroski score, which uses various ratios to give a company a score out of nine. The “sustainability” of the dividend is then calculated using the so-called Merton model — sometimes referred to as “distance-to-default” — which measures the probability that a company will default on its debts.

A look at AstraZeneca’s accounts, however, raises several questions about the stability of its dividend that this “quant” analysis appears to miss. AstraZeneca has been reporting its own version of earnings, “core earnings per share”, that has started to increasingly diverge from earnings based on generally accepted accounting principals (GAAP). This “core EPS” includes gains from one-off events but strips out restructuring and amortisation charges, among other things. The difference between AstraZeneca’s GAAP earnings and “core earnings” has become noticeably large over the past two years. In 2014 “core” EPS was $4.28 while GAAP EPS was just $0.98, and in 2015 “core” EPS was $4.26 while GAAP EPS came in at $2.23.

Once you look past the apparently strong earnings and instead to AstraZeneca’s cash flow generation, the solidity of its high dividend appears less certain. The past two years there has seen a sharp deterioration in AstraZeneca’s free cash flow while it has sharply increased its net debt. In 2015 it would not have been able to pay a $3.4bn dividend out of free cash flow, instead borrowing $4.3bn to plug the gap. The quantitative model appears to be painting a highly divergent picture from the company’s own accounts.

There are similar problems with using the Merton model to monitor the sustainability of a dividend. Certain dividend ETF providers use it as a forward-looking indicator as to the stability of payouts. Morningstar, whose Merton-style “distance-to-default” rating powers BlackRock’s $6bn iShares Core High Dividend ETF (which does not hold AstraZeneca shares), for example, argues that a deteriorating rating has historically proven a strong indication that a dividend is about to get axed.

The Merton model uses the Black-Scholes options pricing model to assess the likelihood that a company’s assets will fall below the value of its liabilities, and is mainly used by credit analysts as a quick and dirty way of measuring the likelihood a company will default. Yet unlike a debt coupon, the decision to pay a dividend is an arbitrary one made by company management — it depends on capital allocation decisions and use of cash flow that are unable to be represented by inputs into the model.

The second issue is that by being based on Black-Scholes, the Merton model is heavily skewed to volatility as the main measure of risk. Shares in large-cap stocks such as AstraZeneca tend to be less volatile, meaning the model is biased to making them appear less risky. By the time the volatility of the shares starts to spike in anticipation of a cut, it is likely to be already too late to avoid large losses.

The weakness of using these models as a “smart” way to invest is that they can only be as good as the assumptions and inputs that go into them. Whatever the marketing tells you, we are still far away from a time when a computer can do all the boring investment chores for us.

(ZH) Deutsche Bank Tells Investors Not To Worry About Its €46 Trillion In Deriva

Deutsche Bank Tells Investors Not To Worry About Its €46 Trillion In Derivatives

Having first flagged Deutsche Bank enormous derivative book for the first time back in 2013, it wasn't until last week that JPMorgan admitted just what the biggest risk facing Deutsche Bank was. In a note by JPMorgan's Nikolaos Panigirtzoglou, the strategist warned that, "in our opinion it is not so much funding issues but rather derivatives exposures that more likely to trouble markets going forward if Deutsche Bank concerns continue. This is especially true if these concerns propagate into a confidence crisis inducing more rapid unwinding of derivative contracts."
For those new to the story, Deutsche has one of the world’s largest notional derivatives books — its portfolio of financial contracts based on the value of other assets. As we first noted in 2013, It peaked at over $75 trillion, about 20 times German GDP, but had shrunk to around $46 trillion by the end of last year. That’s around 12% of the total notional value of derivatives outstanding worldwide ($384 trillion), according to the Bank for International Settlements. It was €46 trillion as of Q2 measured by notional outstanding.
JPMorgan bank analysts confirmed the size of DB's book, and note that BIS data provide an alternative but indirect way to gauge the size of derivatives exposures. According to BIS data the exposure of foreign banks to German counterparties via derivatives contracts stood at $312bn as of Q1 2016.

While the topic of DB's derivative book size emerges any time the bank's stock slides, it tends to be swept under the rug whenever due to fake rumors or otherwise, the stock rebounds.

And in light of yesterday's latest news, in which Germany's Bild reported that Deutsche bank CEO John Cryan "failed to reach an agreement with the US Justice Department", it is possible that on Monday the stock will have an adverse reaction, which also means that attention will once again turn to what JPM believes is the biggest concern for investors for the world's most systematically risky bank.

So what is the embattled German lender, the same one which two weeks ago at the depth of its stock plunge blamed its woes on market "speculators", to do?
As the Chief Risk Officer Stuart Lewis told Welt am Sonntag in an interview published on Sunday, it was to take a preemptive stance on market concerns about Deutsche Bank's staggering derivative position.
Speaking to the German publication, Lewis said that Deutsche Bank continues to cut back the size of its derivatives book, "which is not as risky as investors may believe." Well, not just investors: it also includes that "other" bank with some $53.3 trillion in derivatives, JPMorgan.
"The risks in our derivatives book are massively overestimated," Lewis told the paper cited by Reuters. He said 46 trillion euros in derivatives exposure at Deutsche appeared large but reflected only the notional value of the contracts, while the bank's net exposure to derivatives was far lower, at around €41 billion.
"The 46 trillion euros figure sounds gigantic, but it is completely misleading. The real risk is far lower," Lewis said, adding that the level of risk on Deutsche Bank's books was in line with that seen at other investment banking peers. While he is largely correct about gross notional netting down to a vastly smaller number in a functioning, stable derivatives market in which there is no contagion and all counterparties continue to function during a Deutsche Bank "stress event", that assumption falls out of the window the moment a counterparty fails, and becomes even worse whould any of the underlying derivative collateral be found to have been rehypothecated more than once, something not just we, but the BIS itself warned about in 2013.
But back to Deutsche Bank, whose Chief Risk Officer tried to further belay concerns of a derivative fiasco when he said that "we are trying to make our business less complex and are paring back our derivatives book. Parts of it were transferred into a non-core unit some years ago." While that is true, most of its exposure remains in the core unit (where the deposits are to be found), and what's worse, one wonders why DB hasn't had more success with derisking its gross notional derivative holdings, which still remain a substantial outlier within the European banking system.
More to the point, it is worth recalling that only two short months ago, on July 31, the same Stuart Lewis, when interviewed by Frankfurter Allgemeine said exactly the same thing, in an article titled "We are not dangerous"...
... and promising that concern for the bank in the aftermath of the IMF report labeling it the most systematically risky bank in the world, was unfounded.
When asked if Deutsche Bank is indeed the most important net contributor to systemic risks, he replied:


“No, not at all. Only one IMF report has recently muddled up the situation: We are not dangerous. We are very relevant. Deutsche Bank is interwoven with the entire financial sector. We are one of the largest universal banks in the world. But to make it clear: Our house is stable. The balance sheet is healthy.”


“Absolutely. Look at how we have capitalized the bank since the Financial Crisis. We have taken €115 billion in risks off the balance sheet and have €220 billion of liquidity. Concern for us is unfounded.”
Two months later it turned out that concern for us was, in fact, "founded."
Amusingly, when Wolf Richter pointed out Lewis' comments, he noted that "wisely, Deutsche Bank’s elephantine exposure to derivatives didn’t even come up. It’s better to silence the topic to death than to cause a panic with it."
Now, just over two months later, the topic has come up, and this time Stuart Lewis is scrambling to preempt concerns about the dozens of trillions in derivatives, using the same exact rhetoric: please ignore the elephant in the room; Deutsche Bank is fine.
But the biggest irony from Lewis' August appeal to investors was the following: “The good news is: the taxpayer does not have to step in; according to the new regulations for banks, bondholders will get hit first.” If anything, events over the past two weeks confirmed that this will not happen.
* * *
Still, perhaps an even more important story ahead of Monday's open is not Deutsche Bank's latest attempt to ease investor concerns about its balance sheet and trillions in derivatives, but Friday's report that global banking regulators are sticking to their guns on capital standards in the face of intense European pressure to soften planned rule-changes.
As Bloomberg reported on Friday, the Basel Committee on Banking Supervision will wrap up work on the post-crisis capital framework, known as Basel III, on schedule by the end of the year, William Coen, the regulator’s secretary general, said on Friday. Key elements criticized by European Union policy makers will be retained, according to the text of Coen’s remarks in Washington.


One flashpoint is a proposed new capital floor that caps the benefit banks can gain by measuring asset risk using their own models compared with a formula set by regulators. Coen said “discussions are still under way” on the floor, though Valdis Dombrovskis, the EU’s financial-services chief, called last month for it to be scrapped.
What this means is that as it wraps up Basel III, the regulator is under instructions not to increase overall capital requirements significantly in the process. That promise, first made in January, left open the possibility that individual countries or banks could face a marked increase.
“This is not an exercise in increasing regulatory capital requirements,” Coen said. “However, this does not mean that the minimum capital requirement for all banks will remain the same; variability in risk-weighted assets can only be reduced if there is some impact on the outlier banks. So some banks which are genuinely outliers may face a significant increase in requirements as a result.”
Banks such as Deutsche Bank, which while not named can be inferred: among the most vocal opponents to a boost in overall capital levels is German Finance Minister Wolfgang Schaeuble who has insisted that the Basel Committee not only keep any overall increase in capital requirements to a minimum, but also ensure the rules have no “particularly negative consequences for specific regions,” such as Europe. Or rather, Germany.


In the current round of talks, Europe and Japan are keen to retain risk-sensitivity in the capital rules, including the use of models where appropriate. The European Commission, the EU’s executive arm, doesn’t believe capital floors are an “essential part of the framework,” Dombrovskis said. Europe also opposes the Basel Committee’s proposal to bar some asset classes from modeling entirely, and objects to the calibration of risk-weights in the standardized approach to credit risk.
Why is Europe, and its biggest bank, "keen" on retaining the existing model-based framework which would not require substantial capital increases for risky banks, of which Deutsche Bank is at the very top? Simple: the largest German lender is already notably undercapitalized, and any further capital needs would only lead to further pressure on its stock, forcing it to seel even more equity when the inevitable capital raising moment arrives; it also means that the models used by DB's risk managers are likely to materially misrepresent the bank's true value at risk, not only when it comes to its loan book, and especially Level II and III assets, but more importantly, its derivative book, where while we appreciate Mr. Lewis' assertion that the bank's €46 trillion in gross notional derivatives collapse to just €41 billion, we would be far more interested in seeing the math and assumptions behind this calculation.

FT : Deutsche Bank was given special treatment in stress tests

Deutsche Bank was given special treatment in stress tests
German lender’s result was boosted by a special concession agreed by the European Central Bank


Deutsche Bank was given special treatment in the summer EU stress tests that promised to restore faith in Europe’s banks by assessing all of their finances in the same way.

Germany’s biggest lender, which has its share price fall as much as 22 per cent in recent weeks on fears of a $14bn US fine, has been using the results of the July stress tests as evidence of its healthy finances.

But the Financial Times has learnt that Deutsche’s result was boosted by a special concession agreed by its supervisor, the European Central Bank.

Deutsche’s results included the $4bn proceeds from selling its stake in Chinese lender Hua Xia even though the deal had not been done by the end of 2015, the official cut-off point for transactions to be included.

The Hua Xia sale was agreed in December 2015. It has still not been completed and now faces a delay after missing a regulatory deadline last month, though the bank is still confident of completion this year.

The Hua Xia treatment was disclosed in a footnote to Deutsche’s stress test results. None of the other 50 banks in the stress tests had similar footnotes, even though several also had deals agreed but not completed at the end of 2015.

In one case, Spanish lender Caixabank completed the €2.65bn sale of foreign assets to its parent company Criteria Holding in March but was still not allowed to include the impact of that sale in its results.

“This [Deutsche’s treatment] is perplexing,” said Chris Wheeler, an analyst at Atlantic Equities. “The circumstances mean that it is inevitable the market watchers will be suspicious and have some concern about the veracity of the results.”

Deutsche’s common equity tier one capital fell to 7.8 per cent after the bank was subjected to the stress tests’ imagined doomsday scenario of fines, low interest rates and low economic growth.

Without the Hua Xia boost, the ratio would have been 7.4 per cent, a level comfortably above regulatory minimums. Still, the higher published result helped reassure investors who were growing increasingly nervy about the bank’s capital adequacy.

Nicolas Véron of Bruegel said it was important that both the ECB and the European Banking Authority, which oversaw the tests, could “explain and defend their methodological choices”, especially given the market focus on Deutsche.

“Stress testing methodologies should be applied uniformly and without any special treatment,” he added. “This of course equally applies to banks that are systemically important, such as Deutsche Bank.”

The ECB, is responsible for approving any deviations to the published methodology for banks in the eurozone countries it supervises. The EBA does not have the power to reject deviations.

The ECB said it “treats all banks equally in line with the regulation”. It would not comment on the Deutsche case specifically.

The EBA said that there were more than 20 “one-offs” approved in the stress tests. “The one-offs are designed to avoid obvious anomalies in the forward-looking stress test where events have already taken place in 2015,” the EBA said.

Research by the FT shows that the other “one-offs” were disclosed citing a clause in the methodology that permits limited concessions around “administrative expenses, profit or loss from discontinued operations and other operation expenses”.

The Deutsche disclosure simply says that the results include the proceeds of the Hua Xia sale, which “will be closed in 2016”. There is no effort to reconcile that to the official rules, which say: “any divestments, capital measures or other transactions that were not completed before 31 December 2015, even if they were agreed upon before this date, should not be taken into account in the projections”.

Deutsche declined to comment. The German bank still took a battering from the stress tests: its capital position was hit by 540 basis points, compared with an average in the sample of 380 basis points.

(MS) Multi-Industry : Weakness Continued Through September (full note attached)

Weakness Continued Through September

Our latest US distributor survey sees a profound downside bias to 3Q expectations, given deterioration in September.
Remain cautious on GWW and expensive short cycle names, such as ITW, 3M and ROK.

The major question we hear is whether the rash of pre-announcements that hit last week, most notably from Honeywell, is company-specific or sector-generic?
Our 20th Annual Alphawise US Distributor Survey suggests that there is broad risk to 3Q expectations, given, by far, the greatest downside skew vs. expectations in our survey history, capped off by an unusually weak September. While
distributors are more bullish on forward acceleration, noting election uncertainty, it is clear that inventory headwinds will remain a factor and that weak pricing power will continue to put pressure on distributor gross margins, especially as Amazon is clearly gaining market presence. This keeps us cautious on GWW, since it is in the cross hairs of many of this issues, as well as expensive short cycle "peak-margin" names (ITW, 3M, ROK).

The key findings in more detail are as follows:
* We continue to see a negative bias to growth expectations, similar to trends seen in our six most recent surveys, which predated weaker than expected organic growth results. This quarter, Agriculture Equipment, General Industrial and Defense witnessed the most upside relative to distributor expectations, while Home Building was the only industry that reported positive upside versus previous expectations.
* September appears to have tracked below seasonal norms, with an average 0.9% decline M/M. On the end market level, distributors of Oil & Gas and Agriculture Equipment were the weakest M/M, down 5% and 3% in
September, respectively. Conversely, Automotive, Healthcare and Home Building distributors were stronger in September, all up >1% from August.
* Given the upcoming election, political uncertainties were noted as an overhang on sales, with 48% of respondents pointed to the political environment as a headwind in 3Q. By end market, distributors in the Agriculture Equipment, Defense and Healthcare witnessed the most significant impacts from political uncertainties.
* 2016 growth expectations deteriorated sequentially to -0.3% Y/Y vs. +1.0% in 2Q16.
9 out of 17 end markets forecast volume growth in 2016, with the most bullish expectations in Home Building, Healthcare and Automotive. Meanwhile, O&G, Ag Equipment and General Industrial are expected to be most depressed end markets.

(MS) European Eq. Strat. We update a number of our preferred stock screens to

Buyers’ Compendium – More Value ideas in both Defensives and Cyclicals

We update a number of our preferred stock screens to identify Value ideas that may offer an interesting entry point. 
We update our Buyers’ Compendium to identify stocks that may offer an interesting entry point. 
There are 84 stocks that appear on more than one screen, with 21 stocks being rated Overweight. The latter include: IAG,
Marks& Spencer, BHP Billiton, Continental, EDP, BMW, Caixabank, Covestro, Enagas, Engie, Getinge, Groupe Eurotunnel, Intesa Sanpaolo, Ahold Delhaize, Lafargeholcim, Michelin, Norsk Hydro, Orange, Pearson, Ryanair Holdings and Shire.

Guest screen #1: Defensives with positive earnings revisions. Includes 12 OWs: Imperial Brands, Diageo, Qiagen, Jeronimo Martins, Ahold Delhaize, Astrazeneca, Telecom Italia, SSE, TDC, Telenor, Orange and Iberdrola.

Guest screen #2: Cyclicals that are trading at/close to N12M valuation lows. Includes 6 OWs: Pearson, IAG, BMW, Marks & Spenser, Sky and Groupe Eurotunnel.